← All trials
NCT03643276
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 15, 2018
- Primary completion
- Jul 14, 2028
- Completion date
- Jul 14, 2028
- First posted
- —
- Last posted
- —
- Enrollment
- 5000
- Arms / groups
- 12 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Universitaetsklinikum Schleswig-HolsteinLead sponsor
- Deutsche Krebshilfe e.V.Collaborator
- Universitaetsklinikum Schleswig-HolsteinOverall official - principal investigator
- Universitaetsklinikum Schleswig-HolsteinSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.